Body mass index and height and risk of cutaneous melanoma: Mendelian randomization analyses.
Body mass index
Mendelian randomization
body size
causality
height
melanoma
skin cancer
Journal
International journal of epidemiology
ISSN: 1464-3685
Titre abrégé: Int J Epidemiol
Pays: England
ID NLM: 7802871
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
accepted:
20
01
2020
pubmed:
19
2
2020
medline:
28
4
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Height and body mass index (BMI) have both been positively associated with melanoma risk, although findings for BMI have been less consistent than height. It remains unclear, however, whether these associations reflect causality or are due to residual confounding by environmental and lifestyle risk factors. We re-evaluated these associations using a two-sample Mendelian randomization (MR) approach. We identified single nucleotide polymorphisms (SNPs) for BMI and height from separate genome-wide association study (GWAS) meta-analyses. We obtained melanoma SNPs from the most recent melanoma GWAS meta-analysis comprising 12 874 cases and 23 203 controls. We used the inverse variance-weighted estimator to derive separate causal risk estimates across all SNP instruments for BMI and height. Based on the combined estimate derived from 730 SNPs for BMI, we found no evidence of an association between genetically predicted BMI and melanoma [odds ratio (OR) per one standard deviation (1 SD) (4.6 kg/m2) increase in BMI 1.00, 95% confidence interval (CI): 0.91-1.11]. In contrast, we observed a positive association between genetically-predicted height (derived from a pooled estimate of 3290 SNPs) and melanoma risk [OR 1.08, 95% CI: 1.02-1.13, per 1 SD (9.27 cm) increase in height]. Sensitivity analyses using two alternative MR methods yielded similar results. These findings provide no evidence for a causal association between higher BMI and melanoma, but support the notion that height is causally associated with melanoma risk. Mechanisms through which height influences melanoma risk remain unclear, and it remains possible that the effect could be mediated through diverse pathways including growth factors and even socioeconomic status.
Sections du résumé
BACKGROUND
Height and body mass index (BMI) have both been positively associated with melanoma risk, although findings for BMI have been less consistent than height. It remains unclear, however, whether these associations reflect causality or are due to residual confounding by environmental and lifestyle risk factors. We re-evaluated these associations using a two-sample Mendelian randomization (MR) approach.
METHODS
We identified single nucleotide polymorphisms (SNPs) for BMI and height from separate genome-wide association study (GWAS) meta-analyses. We obtained melanoma SNPs from the most recent melanoma GWAS meta-analysis comprising 12 874 cases and 23 203 controls. We used the inverse variance-weighted estimator to derive separate causal risk estimates across all SNP instruments for BMI and height.
RESULTS
Based on the combined estimate derived from 730 SNPs for BMI, we found no evidence of an association between genetically predicted BMI and melanoma [odds ratio (OR) per one standard deviation (1 SD) (4.6 kg/m2) increase in BMI 1.00, 95% confidence interval (CI): 0.91-1.11]. In contrast, we observed a positive association between genetically-predicted height (derived from a pooled estimate of 3290 SNPs) and melanoma risk [OR 1.08, 95% CI: 1.02-1.13, per 1 SD (9.27 cm) increase in height]. Sensitivity analyses using two alternative MR methods yielded similar results.
CONCLUSIONS
These findings provide no evidence for a causal association between higher BMI and melanoma, but support the notion that height is causally associated with melanoma risk. Mechanisms through which height influences melanoma risk remain unclear, and it remains possible that the effect could be mediated through diverse pathways including growth factors and even socioeconomic status.
Identifiants
pubmed: 32068838
pii: 5739984
doi: 10.1093/ije/dyaa009
pmc: PMC7778056
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1236-1245Informations de copyright
© The Author(s) 2020; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.
Références
J Natl Cancer Inst. 1988 Jul 20;80(10):772-4
pubmed: 3385783
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Cancer Biol Ther. 2009 Oct;8(19):1871-9
pubmed: 19713740
Int J Epidemiol. 2012 Aug;41(4):929-929i
pubmed: 22933644
Int J Epidemiol. 2015 Apr;44(2):662-72
pubmed: 25997436
BMJ. 2016 Mar 08;352:i582
pubmed: 26956984
J Natl Cancer Inst. 2015 Aug 20;107(11):
pubmed: 26296642
Cancer Causes Control. 2012 May;23(5):717-26
pubmed: 22450736
Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
J Invest Dermatol. 2009 Feb;129(2):415-21
pubmed: 18668136
Integr Comp Biol. 2007 Aug;47(2):317-28
pubmed: 21672841
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Nat Genet. 2014 Nov;46(11):1173-86
pubmed: 25282103
Lancet Oncol. 2011 Aug;12(8):785-94
pubmed: 21782509
Cancer Causes Control. 2003 Nov;14(9):847-57
pubmed: 14682442
Am J Epidemiol. 2013 Oct 1;178(7):1177-84
pubmed: 23863760
Hum Mol Genet. 2018 Oct 15;27(20):3641-3649
pubmed: 30124842
Annu Rev Genomics Hum Genet. 2015;16:327-50
pubmed: 25939054
PLoS One. 2015 Jan 22;10(1):e0116863
pubmed: 25612317
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2412-5
pubmed: 24042260
Obes Rev. 2007 Jul;8(4):307-26
pubmed: 17578381
Elife. 2018 May 30;7:
pubmed: 29846171
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Cancer Epidemiol. 2014 Aug;38(4):357-63
pubmed: 24986641
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
JAMA. 2015 Nov 3;314(17):1850-60
pubmed: 26447779
Scand J Soc Med. 1986;14(3):151-60
pubmed: 3489987
Proc Biol Sci. 2018 Oct 24;285(1889):
pubmed: 30355711
Br J Cancer. 2018 May;118(9):1262-1267
pubmed: 29581483
Trends Ecol Evol. 2011 Apr;26(4):175-82
pubmed: 21296451
Cancer Epidemiol. 2016 Feb;40:119-25
pubmed: 26707237
Eur J Cancer. 2013 Feb;49(3):642-57
pubmed: 23200191
Epidemiology. 2014 May;25(3):427-35
pubmed: 24681576
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Toxicol Appl Pharmacol. 2010 May 1;244(3):328-35
pubmed: 20122948
Int J Cancer. 2008 Mar 1;122(5):1100-8
pubmed: 17990316
Br J Cancer. 1981 Dec;44(6):886-91
pubmed: 7326198
Aging (Albany NY). 2016 Jan;8(1):3-11
pubmed: 26805432
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Int J Epidemiol. 2016 Jun;45(3):621-37
pubmed: 27582437
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
Eur J Cancer. 2005 Sep;41(14):2040-59
pubmed: 16125929
Br J Cancer. 2018 Apr;118(8):1123-1129
pubmed: 29555990
Int J Epidemiol. 1990 Dec;19(4):801-10
pubmed: 2084006
Nat Genet. 2015 Sep;47(9):987-995
pubmed: 26237428
Health Rep. 2008 Jun;19(2):61-76
pubmed: 18642520
BMC Public Health. 2008 Jan 25;8:33
pubmed: 18221505
Pigment Cell Melanoma Res. 2017 May;30(3):294-306
pubmed: 28222242
J Photochem Photobiol B. 2015 Oct;151:264-9
pubmed: 26332747
Nat Rev Endocrinol. 2011 Jan;7(1):11-24
pubmed: 20956999
ISRN Prev Med. 2013 Apr 04;2013:680536
pubmed: 24977095
Cancer Causes Control. 2001 Sep;12(7):599-606
pubmed: 11552707
J Epidemiol Community Health. 2019 Aug;73(8):730-736
pubmed: 31053591
Br J Cancer. 2019 Mar;120(5):565-570
pubmed: 30733581
Int J Cancer. 2006 Jan 15;118(2):458-66
pubmed: 16049963
Nature. 2015 Feb 12;518(7538):197-206
pubmed: 25673413
Int J Cancer. 2018 Feb 15;142(4):681-690
pubmed: 28983909